删除或更新信息,请邮件至freekaoyan#163.com(#换成@)

Distinct PD-L1 binding characteristics of therapeutic monoclonal antibody durvalumab

本站小编 Free考研考试/2022-01-02

Shuguang Tan1,
Kefang Liu2,3,
Yan Chai1,
Catherine W. -H. Zhang4,
Shan Gao5,
George F. Gao1,2,3,
Jianxun Qi1
1 CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China;
2 National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention(China CDC), Beijing 102206, China;
3 College of Laboratory Medicine and Life Sciences, Wenzhou Medical University, Wenzhou 325035, China;
4 ImmuFuCell Biotechnology Co. Ltd., Beijing 100102, China;
5 CAS Key Laboratory of Bio-medical Diagnostic, Suzhou Institute of Biomedical Engineering and Technology, Chinese Academy of Sciences, Suzhou 215163, China
Funds: This work was supported by the National Natural Science Foundation of China (Grant Nos. 31390432 and 31500722) and the National Basic Research Program (973 Program) (NO. 2013CB531502),G.F.G. is a leading principle investigator of NSFC Innovative Research Group (Grant No. 81621091).






Abstract



PDF全文下载地址:

http://www.protein-cell.org/article/exportPdf?id=185e9dda-32bb-4ef2-b2ae-c117d3020707&language=en
相关话题/Distinct binding characteristics